Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fox Chase Cancer Center
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Patients must have liver tumors requiring a major liver resection, defined as removing at least three anatomical segments in patients without liver disease and two segments in patients with cirrhosis/fibrosis of the liver.
2. Age \> 18 years.
3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
4. Patients must have acceptable organ and marrow function as defined below:
* White Blood Cells \> 2,000/mcL
* Absolute Neutrophil Count \> 1,000/mcL
* Platelets \> 80,000/mcL
* Alkaline Phosphatase \< 2.5 times institutional upper limit of normal
* Aspartate Aminotransferase/Alanine aminotransferases \< 5 times institutional upper limit of normal
* INR \< 1.5 times institutional upper limit of normal
5. Ability to understand and willingness to sign a written informed consent and HIPAA consent document.
6. Q-T Interval of ≤ 450 ms as measured by EKG.
You may not be if
1. Patients with known hypersensitivity to octreotide or somatostatin.
2. Patients who are receiving any other investigational agents.
3. Patients who are taking other medications that prolong QT interval.
4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
5. Pregnant or breast feeding.
Clareo Health | Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy
